Labradimil

DCTPepD ID  DCTPepD0067

Active Ingredients   Labradimil

Description  A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB). Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life.

Synonyms  Cereport; DRG-0182; L-Prolinamide, L-Arginyl-L-prolyl-trans-4- hydroxy-L-prolyl-3-(2- thienyl)-L-alanylglycl -L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1- -carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (S-(R*,R*)); RMP-7; Labradimil; Lobradimil

Disease  Brain cancer

Classification

  

Bradykinin agonists Peptide and derivative

Structure Information


Molecular Formula  C49H75N15O12S

Molecular Weight  1098.3

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-methoxyphenyl)propyl]amino]-5-(diaminomethylideneamino)pentanoic acid

InChI  InChI=1S/C49H75N15O12S/c1-76-31-14-12-28(13-15-31)21-29(24-57-34(47(74)75)9-3-17-56-49(53)54)59-43(70)37-10-4-18-62(37)45(72)36(27-65)61-41(68)35(23-32-7-6-20-77-32)60-40(67)25-58-42(69)39-22-30(66)26-64(39)46(73)38-11-5-19-63(38)44(71)33(50)8-2-16-55-48(51)52/h6-7,12-15,20,29-30,33-39,57,65-66H,2-5,8-11,16-19,21-27,50H2,1H3,(H,58,69)(H,59,70)(H,60,67)(H,61,68)(H,74,75)(H4,51,52,55)(H4,53,54,56)/t29-,30+,33-,34-,35-,36-,37-,38-,39-/m0/s1

InChI_Key IDXCXSCCZNCXCL-XMADEQCMSA-N

SMILES  O=C(O)[C@@H](NC[C@@H](NC([C@H]1N(C([C@@H](NC([C@@H](NC(CNC([C@H]2N(C([C@H]3N(C([C@@H](N)CCC/N=C(N)\N)=O)CCC3)=O)C[C@H](O)C2)=O)=O)CC4=CC=CS4)=O)CO)=O)CCC1)=O)CC5=CC=C(OC)C=C5)CCC/N=C(N)\N

External Codes


PubChem CID  6918284

DrugBank Accession Number  DB06549

NCI Thesaurus Code  C1606  

UNII  2MK663C346   GSRS

CAS  159768-75-9



Drug approval


Drug indication
    Investigated for use/treatment in brain cancer and pediatric indications.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00005602 Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas Brain and Central Nervous System Tumors Phase 1 Treatment
NCT00001502 Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors Brain Neoplasms; Glioma; Medulloblastoma Phase 1 Treatment
NCT00019422 A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors Brain and Central Nervous System Tumors Phase 2 Treatment
NCT00002316 Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis Meningitis, Cryptococcal; HIV Infections Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.